Search

Your search keyword '"Lanctôt, Krista L."' showing total 330 results

Search Constraints

Start Over You searched for: Author "Lanctôt, Krista L." Remove constraint Author: "Lanctôt, Krista L." Database Unpaywall Remove constraint Database: Unpaywall
330 results on '"Lanctôt, Krista L."'

Search Results

1. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)

4. Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis

5. Heterogeneity of Cognition in Older Adults with Remitted Major Depressive Disorder: A Latent Profile Analysis

7. Reduction of agitation and caregiver distress using a combination intervention of tetrahydrocannabinol and melatonin in dementia due to Alzheimer disease

9. Investigating the effects of aerobic exercise primed anodal transcranial direct current stimulation on γ‐aminobutyric acid concentrations in mild vascular cognitive impairment

10. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial

11. Beta to Theta Power Ratio in Electroencephalogram Periodic Components to Discriminate Mild Cognitive Impairment and Alzheimer’s Dementia

15. Reduction of neuropsychiatric symptoms and associated caregiver distress using a tetrahydrocannabinol and melatonin combination in dementia due to Alzheimer’s disease

17. Investigating the impact of hypertension with and without diabetes on progression to Alzheimer’s disease: A clinic‐pathological study

18. Effect of tetrahydrocannabinol and melatonin combination on suicide ideation and behavior in dementia due to Alzheimer’s disease

19. Risk of motor vehicle collisions and culpability among older drivers using cannabis: a meta‐analysis

21. Reduction of apathy and caregiver distress using a combination of tetrahydrocannabinol and melatonin in dementia due to Alzheimer’s disease

22. Associations between homocysteine, tau, and neurodegenerative markers in apolipoprotein ε4 non‐carriers with clinical Alzheimer’s disease

23. Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders

24. Effect of the combination of tetrahydrocannabinol and melatonin (IGC‐AD1) on blood pressure variability in patients with mild to moderate Alzheimer’s Disease

25. Blood‐based biomarkers for predicting treatment response in the Apathy in Dementia Methylphenidate Trial 2 randomized clinical trial

26. Circulating cell‐free mitochondrial DNA (ccf‐mtDNA) and memory in mild cognitive impairment (MCI) and Alzheimer’s disease (AD)

27. Association between lipopolysaccharide, immune biomarkers and cerebral amyloid‐beta deposition in older adults with mild cognitive impairment & major depressive disorder

31. Self- versus informant-report of cognitive decline in mild cognitive impairment: Concordance with cognitive and functional performance.

32. No association between metformin initiation and incident dementia in older adults newly diagnosed with diabetes

33. Cytochrome P450-soluble epoxide hydrolase derived linoleic acid oxylipins and cognitive performance in type 2 diabetes

35. Contributors

36. Association of sulfonylureas with the risk of dementia: A population‐based cohort study

37. Boswellic Acids Improve Clinical Cognitive Scores and Reduce Systemic Inflammation in Patients with Mild to Moderate Alzheimer’s Disease

38. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)

40. Risk of Motor Vehicle Collisions and Culpability among Older Drivers Using Cannabis: A Meta-Analysis

42. Soluble Epoxide Hydrolase Derived Linoleic Acid Oxylipins, Small Vessel Disease Markers, and Neurodegeneration in Stroke

43. Association of sodium-glucose cotransporter-2 inhibitors with time to dementia: a population-based cohort study

44. Association of sodium-glucose cotransporter-2 inhibitors with time to dementia: a population-based cohort study

45. Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study

46. Variability of response to exercise‐primed tDCS in those with mild cognitive impairment and Alzheimer’s disease (the EXPRESS study): a preliminary analysis

48. Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial

49. Association of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors with time to dementia: a population‐based cohort study

50. Boswellic acids (K‐Vie ™ ) improves clinical cognitive scores and reduces systemic inflammation in patients with mild to moderate Alzheimer’s disease.

Catalog

Books, media, physical & digital resources